Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial

Autor: Schwentner, Lukas, Harbeck, Nadia, Singer, Susanne, Eichler, Martin, Rack, Brigitte, Forstbauer, Helmut, Wischnik, Arthur, Scholz, Christoph, Huober, Jens, Friedl, Thomas W.P., Weissenbacher, Tobias, Härtl, Kristin, Kiechle, Marion, Janni, Wolfgang, Fink, Visnja
Zdroj: In The Breast June 2016 27:69-77
Databáze: ScienceDirect
Externí odkaz: